Unsold goods pile up at US factories as growth slows; JLR shutdown hits UK manufacturing – business live | Business

US business growth slows as stock piles up at American factories

Just in: Business growth across the US is slowing this month, due to a softening of demand growth across both manufacturing and the services sector.

The latest poll of purchasing managers at American companies has found that levels of unsold stock at US factories has jumped this month, at the fastest rate in the survey’s history.

🇺🇸 US Manufacturing PMI fell to 52.0, with slower growth in output & new orders. Disappointing sales led to the largest build-up of unsold finished goods ever. Services PMI dropped to 53.9 due to weaker domestic demand. Input costs rose to a near 27-month high but firms struggled… pic.twitter.com/20Hm69eSnP

— Augur Infinity (@AugurInfinity) September 23, 2025

S&P Global, which conducts the PMI survey, reports that growth has weakened for a second successive month in September.

Comapnies also blamed tariffs as being the principal cause of further cost increases in September, most evidently in the manufacturing sector.

Chris Williamson, chief business economist at S&P Global Market Intelligence, says:

“Further robust growth of output in September rounds off the best quarter so far this year for US businesses. PMI survey data are consistent with the economy expanding at a 2.2% annualized rate in the third quarter.

However, the monthly profile is one of growth having slowed from its recent peak back in July, and September saw companies also pull back on their hiring. Softening demand conditions are also becoming more widely reported, curbing pricing power.

Although tariffs were again cited as a driver of higher input costs across both manufacturing and services, the number of companies able to hike selling prices to pass these costs on to customers has fallen, hinting at squeezed margins but boding well for inflation to moderate.

This pulled S&P Global’s flash US Composite PMI output index down to 53.6, a three-month low, showing a slowdown in growth.

Key events

Kenvue shares shrug off Trump’s claims

Julia Kollewe

Julia Kollewe

Shares in Tylenol maker Kenvue bounced back today, recovering much of of yesterday’s losses when Donald Trump said pregnant women should limit their use of Tylenol, the US brand name for paracetemol. He claimed it heightens the risk of autism in children – a claim contested by scientists and contradicted by studies.

Wes Streeting, the UK health secretary, firmly rejected the US president’s claims today.

He told ITV’s Lorraine:

“I’ve just got to be really clear about this: there is no evidence to link the use of paracetamol by pregnant women to autism in their children. None.

“In fact a major study was done back in 2024 in Sweden, involving 2.4 million children, and it did not uphold those claims. So I would just say to people watching: don’t pay any attention whatsoever to what Donald Trump says about medicine. In fact, don’t even take my word for it as a politician. Listen to British doctors, British scientists, the NHS.”

Kenvue shares fell more than 7% yesterday after Trump’s intervention, hitting their lowest level since the consumer health company was spun out of US drugmaker Johnson & Johnson in 2023. The stock rose more than 6% in early trading in New York today.

Kenvue has been touted by analysts as a potential takeover target for Haleon, which was itself spun from British phamaceutical giant GSK three years ago. Kenvue is under pressure from activist investors to offload underperforming brands.

AJ Bell investment director Russ Mould said:

“Despite President Trump suggesting a link between Tylenol and autism the company behind the branded paracetamol – Kenvue – did not suffer too much pain in the end overnight, paring earlier losses. Though the shares are down meaningfully since the first murmurings from the administration on a possible link earlier this month.”

Kenvue’s market value has fallen from $40bn in mid-August to less than $35bn today. In July, its board fired chief executive Thibaut Mongon, paving the path for what investors said they hope will be the eventual sale of the company. Kenvue’s other major brands include Listerine and Band Aid.

Leave a Reply

Your email address will not be published. Required fields are marked *

Bale News
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.